Metoprolol
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Metoprolol: From Hypertension and Heart Failure to Malignant Hypertensive Renal Disease
One-Sentence Summary
Metoprolol is a selective beta-1 adrenergic blocker with established clinical use in hypertension, angina pectoris, and heart failure. The TxGNN model predicts it may be effective for Malignant Hypertensive Renal Disease, with 0 clinical trials and 0 publications currently supporting this specific direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Hypertension, Angina Pectoris, Heart Failure (established global clinical use; no India regulatory approval on record) |
| Predicted New Indication | Malignant Hypertensive Renal Disease |
| TxGNN Prediction Score | 99.91% |
| Evidence Level | L5 |
| India Market Status | Not marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in this Evidence Pack. Based on established pharmacology, Metoprolol is a cardioselective beta-1 (β₁) adrenergic receptor antagonist. By selectively blocking β₁ receptors, it reduces heart rate and cardiac output while inhibiting renin release from juxtaglomerular cells in the kidney. This dual action — lowering systemic blood pressure and blunting the renin-angiotensin-aldosterone cascade — provides a theoretical basis for its consideration in hypertension-driven renal injury.
In malignant hypertensive renal disease, uncontrolled severe hypertension causes fibrinoid necrosis of afferent renal arterioles and progressive ischemic nephron loss. Aggressive blood pressure reduction is the primary therapeutic goal, and agents that reduce cardiac output and renin-mediated vasoconstriction — both properties of Metoprolol — could theoretically attenuate this vascular injury cascade. The mechanistic link is therefore biologically plausible, though indirect.
However, current clinical practice reserves beta-blockers as adjunctive agents in hypertensive renal disease, preferring ACE inhibitors and ARBs as first-line therapy for their direct renoprotective RAAS-blocking effects. No controlled trials have directly evaluated Metoprolol in malignant hypertensive renal disease, leaving this TxGNN prediction without empirical clinical validation.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
India Market Information
Metoprolol is currently not marketed in India. No registered licenses or authorizations are on record in the CDSCO database as reflected in this Evidence Pack.
Safety Considerations
Drug Interactions (337 total interactions identified; representative highlights below):
| Interacting Drug | Interaction Level |
|---|---|
| Epinephrine | Moderate |
| Hydrocortisone | Moderate |
| Hyoscyamine | Moderate |
| Bupropion | Moderate |
| Triamcinolone | Moderate |
| Morphine | Moderate |
| Atropine | Moderate |
| Dexamethasone | Moderate |
| Cimetidine | Moderate |
| Canagliflozin | Moderate |
| Dapagliflozin | Moderate |
| Betamethasone | Moderate |
| Budesonide | Moderate |
| Chlorpropamide | Moderate |
| Calcium Phosphate | Moderate |
| Lorcaserin | Moderate |
| Calcium acetate | Moderate |
| Glycopyrronium | Moderate |
| Acetylsalicylic acid | Minor |
| Magnesium oxide | Minor |
Please refer to the package insert for complete safety information, including key warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: No clinical trials or published literature directly support Metoprolol for malignant hypertensive renal disease, placing this prediction at the lowest evidence level (L5). Current guidelines favor ACEi/ARB as the primary renoprotective strategy in this setting, limiting Metoprolol to a supporting role without dedicated trial data.
To proceed, the following is needed:
- Full mechanism of action (MOA) data from DrugBank to formally confirm relevance of the β₁-selective renal renin pathway
- Systematic literature review or pilot observational study examining beta-blocker add-on therapy specifically in malignant hypertensive renal disease
- CDSCO package insert data to clarify key warnings, contraindications, and renal-impairment dosing guidance
- Comparative assessment of whether Metoprolol’s β₁-selectivity confers safety advantages over non-selective beta-blockers in patients with concurrent renal failure
- Renal function monitoring protocol design (creatinine, eGFR, electrolytes) before any prospective investigation
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.